BofA/Merrill Lynch Upgrades AstraZeneca (AZN) to Neutral
Tweet
Share
E-mailGet Alerts AZN Hot Sheet
Price: $70.13 --0%
Rating Summary:
17 Buy, 8 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 10 | New: 13
Rating Summary:
17 Buy, 8 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 10 | New: 13
Join SI Premium – FREE
BofA/Merrill Lynch upgraded AstraZeneca (NYSE: AZN) from Underperform to Neutral.
For an analyst ratings summary and ratings history on AstraZeneca click here. For more ratings news on AstraZeneca click here.
Shares of AstraZeneca closed at $43.90 yesterday.
For an analyst ratings summary and ratings history on AstraZeneca click here. For more ratings news on AstraZeneca click here.
Shares of AstraZeneca closed at $43.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab
- Wells Fargo Upgrades Datadog (DDOG) to Overweight
- Geopolitical shocks should be bought, not sold - BofA
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
